Local lawyer looks to bring new perspective to Dayton City Commission
DAYTON, Ohio (WDTN) — 2 NEWS is highlighting each candidate for Dayton City Commission ahead of the May 6 election.
In just six days, five candidates will face off, with four being voted to go onto the November ballot to ultimately fill two commission seats.
2 NEWS will be sharing more on each candidate in reverse alphabetical order — today sharing more about Attorney Jacob Davis.
Davis is a proud Daytonian, an attorney at Nalls and Davis Law Firm and a former Human Resource Center employee for the city of Dayton.
'I want to be a Dayton city commissioner because I love this community, I chose to stay here, I'm a small business owner here and I bring a unique skill set,' said David.
Daivs is running for commission with hopes to positively engage with Dayton youth and revitalize Dayton neighborhoods.
'I have to work on our neighborhoods. We have to have policies, land use policies and grant programs that prioritize beautification, development, sustainability of neighborhoods first and foremost,' said Davis.
Davis is a graduate of the University of Dayton, and says that the city has not seen a lawyer on the commission for two decades, something that he says sets him apart.
'Litigating civil rights cases in federal and state court, I know how to find solutions to tough issues. And I think that that helps me stand out,' said Davis.
He says his personal love for Dayton runs deep.
'I'm a husband to my wife, and we have a three-year-old daughter. Every decision that I make as a commissioner will be premised on leaving my daughter a better city,' said Davis.
To learn more about Jacob Davis, visit his campaign website.
2 NEWS will share profiles on each candidate in the coming weeks. Click here to see full coverage of the 2025 Dayton City Commissioner race, including other profiles as they become available.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
Chipotle introduces new dip as ‘bold new flavor'
DAYTON, Ohio (WDTN) — For the first time in five years, Chipotle is adding a brand new sauce to its menu. Starting June 17, Chipotle locations across the U.S. and Canada will offer Adobo Ranch. According to the chain, the new sauce is described as being a smoky and spicy twist on ranch. The new sauce is made of adobo pepper, sour cream and various herbs and spices. According to Chris Brandt, president and chief brand officer at Chipotle, Gen Z has contributed to making ranch 'a cultural phenomenon.' 'Our new Adobo Ranch taps into this passion, giving fans a craveworthy way to customize their Chipotle order with a completely new flavor,' said Brandt. On the first offering day, Chipotle Rewards members can receive a free offer for the new sauce with a minimum purchase of $5 on their account. Accounts must be made by 11 p.m. local time on June 16. In 2020, the company introduced Queso Blanco to its customers nationwide. To learn how to create an Chipotle Rewards account, click here. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
8 hours ago
- Yahoo
FibroBiologics Appoints Jason D. Davis, CPA, as Chief Financial Officer
Seasoned finance executive brings over 20 years of public company and capital markets experience to support clinical-stage growth HOUSTON, June 09, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ('FibroBiologics'), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced the appointment of Jason D. Davis, CPA, as Chief Financial Officer, effective immediately. Mr. Davis brings extensive experience in corporate finance, capital markets, and SEC reporting, with a proven track record of successfully leading companies through critical growth phases, including IPOs and capital raising initiatives. His appointment comes as FibroBiologics advances toward its Phase 1/2 clinical trial for diabetic foot ulcers in the second half of 2025 and continues to expand its fibroblast-based therapeutic platform. 'Jason brings exactly the kind of experience and leadership we need at this pivotal moment. His deep understanding of public company operations and capital markets isn't just helpful — it's a force multiplier as we move our lead program into the clinic. He knows how to raise capital in a complex biotech environment, and that makes him a critical part of our mission to drive long-term innovation and deliver exceptional value to shareholders,' commented Pete O'Heeron, FibroBiologics' Founder, Chairman and Chief Executive Officer. Mr. Davis added, 'FibroBiologics, with its fibroblast-based platform, strong intellectual property portfolio, and well-defined clinical strategy, offers a truly differentiated approach to the development of therapeutics and potential cures for chronic diseases, and has all the elements of a high-growth, high-impact enterprise. I'm excited to bring my experience in public company finance to the table as we execute, scale, and deliver meaningful value — not just for shareholders, but for patients around the world.' Mr. Davis most recently served as Chief Financial Officer of Virax Biolabs, where he helped navigate the company through its successful IPO in July 2022. During his tenure, he led multiple capital raises with favorable terms, managed all periodic reports and other filings with the SEC, and implemented public company governance best practices. Prior to Virax, Mr. Davis served in various finance roles for several public companies, including HyperDynamics Corp, where he increased the company's market cap from $20 million to over $700 million and raised over $200 million in multiple transactions from U.S. and European capital markets. He received his B.B.A. in Accounting from the University of Houston and is a CPA certified in Texas. For more information, please visit FibroBiologics' website or email FibroBiologics at info@ Cautionary Statement Regarding Forward-Looking Statements This communication contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include information concerning plans for, and the timing of, clinical trials, and the role to be played by, and impact of, the Chief Financial Officer. These forward-looking statements are based on FibroBiologics' management's current expectations, estimates, projections and beliefs, as well as a number of assumptions concerning future events. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside FibroBiologics' management's control, that could cause actual results to differ materially from the results discussed in the forward-looking statements, including those set forth under the caption "Risk Factors" and elsewhere in FibroBiologics' annual, quarterly and current reports (i.e., Form 10-K, Form 10-Q and Form 8-K) as filed or furnished with the SEC and any subsequent public filings. Copies are available on the SEC's website, These risks, uncertainties, assumptions and other important factors include, but are not limited to: (a) risks related to FibroBiologics' liquidity and its ability to maintain capital resources sufficient to conduct its business; (b) expectations regarding the initiation, progress and expected results of our R&D efforts and preclinical studies; (c) the unpredictable relationship between R&D and preclinical results and clinical study results; and (d) the ability of FibroBiologics to successfully prosecute its patent applications. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and FibroBiologics assumes no obligation and, except as required by law, does not intend to update, or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. FibroBiologics gives no assurance that it will achieve its expectations. About FibroBiologics Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 275+ US and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy and tissue regeneration. For more information, visit General Inquiries:info@ Investor Relations:Nic JohnsonRusso Partners(212) 845-4242fibrobiologicsIR@ Media Contact:Liz PhillipsRusso Partners(347)
Yahoo
19 hours ago
- Yahoo
Salary cap impact of Jaguars releasing Gabe Davis with post-June 1st designation
The Jacksonville Jaguars announced on Wednesday that they were releasing wide receiver Gabe Davis, and on Thursday afternoon, that move became official. Davis was waived with failed physical and post-June 1st designations, according to Aaron Wilson. As it pertains to the post-June 1st designations, that does come with some noteworthy salary cap ramifications for both 2025 and 2026. Advertisement Last offseason, Davis signed a three-year, $39 million deal with $24 million guaranteed. By releasing Davis at this point, the Jaguars are taking on a hefty amount of dead cap--which are dollars that have been paid to the player but not yet accounted for on the salary cap--of $20.3 million. The decision that the Jaguars had was to either absorb that full $20.3 million in dead cap on the 2025 salary cap, but be out from under Davis' deal in 2026, or use the post-June 1st designation to spread the dead cap hit out. By choosing the latter, Davis will leave behind a dead cap hit of $5.7 million in 2025, but also a $14.6 million dead cap hit in 2026, according to Over the Cap. So even though Davis will be playing elsewhere, he will still be on the Jaguars' salary cap books for each of those amounts over the next two seasons. This article originally appeared on Jaguars Wire: Salary cap impact of releasing Gabe Davis with post-June 1st designation
